CABA APS: Financial statements 2024
CVR: 39691825
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
CABA APS (CVR 39691825) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -3,125 and a net result of DKK -3,125 compared with DKK -3,125 the year before. Equity in the 2024 report amounted to DKK 28,125. The solvency ratio was 56.3%.
- Gross Profit
- DKK -3,125
- Profit/Loss
- DKK -3,125
- Equity
- DKK 28,125
- Total Assets
- DKK 50,000
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | -3 t. | -3 t. | 28 t. | 0 |
| 2023 | - | -3 t. | -3 t. | 31 t. | 0 |
| 2022 | - | -3 t. | -3 t. | 34 t. | 0 |
| 2021 | - | -3 t. | -3 t. | 38 t. | 0 |
| 2020 | - | -3 t. | -3 t. | 41 t. | 0 |
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
CABA APS has published its annual report for 2023. Gross profit came to DKK -3,125, and the net result was DKK -3,125.
About CABA APS
CABA APS is a Danish company of the type Anpartsselskab based in Fårevejle, founded in 2018. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named ACBA APS. The management consists of Henrik Nakskov and Søren Luplau-Pagh. The company is owned by Devopharma ApS. In 2025, the company reported a gross profit of DKK -3,125 and a net result of DKK -3,125 compared with DKK -3,125 the year before. Equity in the 2025 report amounted to DKK 25,000.